Tupelo Data Room

pharmacy for Sale

Explore pharmacy for sale. Compare opportunities and connect with sellers.

Pharmacies

Licensed Retail Pharmacy Platform, 503a Sterile Compounding Equipment

Pearland, Brazoria County, TX, US

Confidential opportunity to acquire or strategically partner with an established licensed retail pharmacy platform located in the Pearland / Greater Houston, Texas market. The business operates from an existing pharmacy facility and combines traditional prescription dispensing with third-party payer/PBM access, delivery and digital capabilities, a two-pharmacist team, and sterile/non-sterile compounding equipment and infrastructure available. The company has acquired sterile/nonsterile compounding equipment and infrastructure (currently in storage and is positioned for implementation. The pharmacy has demonstrated the ability to process prescriptions across a broad payer base, with historical activity involving major commercial and government channels. Current/historical documentation includes CVS Caremark-related activity, Medicare Part D, Humana, Aetna, Optum / Prescription Solutions and other managed-care payers. The operating platform provides a potential strategic buyer with an existing licensed pharmacy, personnel, dispensing workflow and reimbursement infrastructure rather than requiring a greenfield build. Company reporting for 2025 reflects approximately $1.98 million of prescription revenue, approximately $1.38 million of prescription-level gross profit and approximately 2,221 prescriptions, representing a reported Rx-level gross margin of approximately 69.9%. The supplied 2026 transaction file through the available period contains 880 fill transactions, approximately $486,000 of revenue, approximately $172,000 of acquisition cost and approximately $314,000 of reported transaction-level gross profit. Revenue has declined from prior peak periods, creating a different type of strategic opportunity: the facility, pharmacy licenses, payer relationships, pharmacist staffing and available compounding infrastructure may have significant value to an operator capable of introducing immediate prescription or fulfillment volume. Ownership is willing to entertain significant and meaningful strategic arrangements with qualified parties that can bring business to the platform, including fulfillment agreements, joint ventures, strategic investments and acquisition structures involving continued seller equity participation. The pharmacy also has sterile and non-sterile compounding equipment available and is positioned for further development of personalized medicine and compounding services, subject to all applicable licensing, certification, regulatory and operational requirements. This creates potential upside for a qualified operator seeking an existing pharmacy base from which to build higher-value prescription, provider, telehealth, wellness or compounding programs. · Licensed Operating Platform – Existing Texas Class A Retail Pharmacy License and DEA registration, with an established Pearland pharmacy facility. · Existing PBM / Payer Access – Contracted across various commercial, Medicare, Medicaid and managed-care channels, including CVS Caremark related activity. · Two-Pharmacist Team – Existing pharmacist staffing (1 Pharmacist, 1 Pharmacist Owner, 2 Techs) supports continuity and provides an operating base for incremental prescription volume. · Attractive Historical Rx-Level Economics – 2025 pharmacy-system reporting reflects approximately $1.98M of Rx revenue and approximately $1.38M of Rx-level gross profit. 2026 Revenue has seen a significant decline, at $486k Gross Revenue through Sept 2026. · Strategic Fulfillment Capacity – Existing pharmacy infrastructure may allow a strategic buyer or partner to introduce prescription volume without creating a pharmacy platform from the ground up. · Flexible Transaction Structures – Seller is open to meaningful fulfillment, JV, strategic investment and equity-roll opportunities with qualified counterparties capable of bringing immediate business.

$199,918Asking Price
$486,000Revenue
-Cash Flow
Pharmacies

503a Sterile Compounding Pharmacy Licensed in 39 States - Contract Pen

Confidential

Confidential Sale - Contract Pending 503a Sterile Compounding Pharmacy, Licensed in 39 States. The business has a longstanding operating history, specialized compounding infrastructure, and an experienced clinical and pharmacy support team. The pharmacy serves patients, prescribing practitioners, and veterinary clients with customized pharmaceutical preparations. Its services encompass specialty formulations, hormone replacement therapies, low-dose naltrexone, veterinary compounds, and other individualized prescription solutions. The operation includes an established Pharmacist-in-Charge, additional compounding pharmacists, trained pharmacy technicians, and personnel supporting prescription processing, fulfillment, and distribution.

$6,000,000Asking Price
$2,878,841Revenue
-Cash Flow
Medical Practices
Pharmacies

$7.6m EBITDA Specialty Pharmacy (Confidential)

Austin, Travis County, TX, US

Multi-site specialty pharmacy platform licensed in 14 states with integrated secondary fulfillment. The Company enjoys strong & stable financial performance, with consistent revenue and high operating margins. The Company’s experienced management team has proven their operational expertise, and is willing to remain onboard. Each department has been built out to support the operation, offering complete coverage from onboarding and business development teams, through fulfillment, compliance, customer support and billing. Services include prescriptions, compounding, medication therapy management, home delivery, and clinical support. Multiple locations, with centralized fulfillment capabilities for other states. Investment Highlights Attractive Unit Economics: High gross margins and strong EBITDA conversion rates. Diversified Revenue Streams: The Company is a leader in and maintains expertise in workflow, and processing for various types of patients, related to payors known for high reimbursements. Diverse Referral Base: The Company receives referrals from 100s of Clinics in the region. No one referral source accounts for a large percentage of Regulatory & Operational Moat: Multi-state licensure and HIPAA-compliant fulfillment operations. Technology-Enabled Operations: Automated refill, synchronization, and next-day delivery systems. Experienced Leadership: Management Team alone possesses over 80+ years combined pharmacy and healthcare management experience. Full Revenue Cycle: Well established and currently at full revenue cycle. Proven Scalability: Turnkey platform ready for add-on acquisitions and new market expansion. CONFIDENTIAL SALE. PROOF OF PORTFOLIO OR RELATED HEALTHCARE INDUSTRY / INVESTMENT BACKGROUND REQUIRED PRIOR TO RELEASE OF CONFIDENTIAL INFORMATION.

-Asking Price
$11,238,357Revenue
$7,577,566Cash Flow
Specialty Pharmacy  | 340B Contract  photo
Other Health Care & Fitness
+1

Specialty Pharmacy | 340B Contract

FL, US

Established in 2004, this premier South Florida specialty pharmacy and wholesale enterprise generates $22.59M in normalized annual revenue while dispensing an average of ~550 prescriptions daily. Operating out of a 10,000 sq. ft. facility footprint with a tenured staff of 23, the business combines a high-margin specialty dispensing footprint with a rare Florida wholesale distribution license. Unmatched Competitive Moats & Revenue Drivers 340B Contract Advantage: Holds an active 340B contract pharmacy relationship, expanding profit margins on high-cost specialty medications. Rare Florida Wholesale License: Includes an active Florida retail wholesale distribution license—a scarce, highly sought-after asset that serves as a massive barrier to entry and opens B2B expansion channels. High-Margin HIV Collaborative Agreement: Newly executed collaborative agreement permits direct HIV testing and prescribing under 340B in a top national demand market. Full Payer Access & Institutional Network: Fully in-network with all major insurance carriers/PBMs, backed by an established detox/LTC facility referral channel. Immediate Consolidation Synergy: Merging duplicate operations instantly eliminates redundant rent, payroll, and licensing fees, driving an estimated ~$180,000 directly to the bottom-line net profit. Next Steps High-volume 340B specialty pharmacies with active wholesale distribution licenses in Florida rarely hit the open market. Serious prospective buyers must execute a Non-Disclosure Agreement (NDA) and provide Proof of Funds to receive the complete Confidential Information Memorandum (CIM) and financial package. Contact AcquiTrust M&A Advisory today to secure your position! — AcquiTrust | Owner-Led. AI-Powered. Acquisition Specialists.

$7,000,000Asking Price
$22,593,184Revenue
$1,588,579Cash Flow
Independent Pharmacy with Significant Growth Potential photo
Pharmacies

Independent Pharmacy with Significant Growth Potential

Blanco County, TX, US

Confidential opportunity to acquire an established independent pharmacy serving a solid, growing Texas Hill Country market. The business is currently operating with a simple model focused primarily on prescription filling, creating substantial upside for a buyer with the vision and operational experience to expand services and unlock additional revenue streams. This is an excellent opportunity for a regional group or strategic acquirer seeking to add a community-based location with meaningful growth potential. It is equally well suited for a younger pharmacist, including one looking to build a long-term future for themselves and their family in a wholesome, down-home Texas small-town community with strong values and an appealing quality of life. At present, the pharmacy’s limited service mix leaves clear room for expansion through value-added offerings such as immunizations, medication synchronization, adherence packaging, delivery, compounding, provider outreach, front-end merchandising, and other patient-centered services. A buyer who can execute on these opportunities may be able to significantly enhance both revenue and overall enterprise value. The pharmacy benefits from an established presence, local customer relationships, and a community setting where personal service and healthcare access matter. Seller is seeking a smooth transition and will consider qualified buyers who appreciate the long-term potential of the business and the market it serves. Additional information available to qualified buyers upon execution of a confidentiality agreement.

$276,421Asking Price
$1,400,000Revenue
$120,000Cash Flow
Multi-License Specialty Pharmacy Platform-340B, Compounding, Infusion photo
Pharmacies

Multi-License Specialty Pharmacy Platform-340B, Compounding, Infusion

FL, US

AcquiTrust Exclusive! Rare opportunity to acquire a fully licensed, fully accredited specialty pharmacy platform combining three complementary operations under one transaction: a community retail pharmacy, a closed-door specialty pharmacy holding active 340B contract pharmacy agreements, and an ambulatory infusion suite operating within the same facility. What makes this platform difficult to replicate: 17 non-resident pharmacy licenses. Multi-state licensure is the single largest barrier to entry in specialty pharmacy. Building this footprint independently takes two to three years of applications, inspections, and fees. It transfers with this transaction, and the current owner will remain engaged to support the transition. ACHC accreditation under USP 795 and 797 covering sterile, non-sterile, hazardous, and non-hazardous compounding. The facility and clean room are already built, inspected, and accredited. This is a functioning compounding operation, not a plan for one. Three 340B contract pharmacy agreements, recently executed. Contract one is live and currently servicing approximately 25 patients per month through an STD clinic, with volume growing. Contract two goes live in October and represents substantial upside — it serves a federally qualified health center whose commercial BCBS panel alone is approximately 1,500 lives. The health center is dissatisfied with its incumbent pharmacy provider's service levels, and the expectation is exclusive provider status. Contract three is executed and pending activation. Ambulatory infusion suite already operating inside the pharmacy, providing a second revenue channel and a natural referral path from the specialty book. Immediate conversion path to 503A sterile compounding. Because the facility already holds 795/797 ACHC accreditation, the buildout, equipment, and quality systems required for a 503A sterile compounding operation are largely in place. For a buyer targeting the peptide compounding market, the conversion is a matter of registration and process rather than construction and capital. The opportunity — stated plainly This platform is being sold on its infrastructure, licensing, and contracted growth pipeline, not on trailing earnings. Current operations are not profitable, and the reason is specific and correctable: the pharmacy is not sourcing medications at optimal acquisition cost. As a result, a meaningful share of scripts carry negative margin and are being routed away to payer mail-order facilities rather than filled in-house. This is a purchasing and wholesaler-terms problem, not a demand problem. Script volume is present. The infrastructure to fill is present. The licensing to fill across state lines is present. A buyer with an existing GPO relationship, established wholesaler terms, or the working capital to normalize purchasing captures margin on volume that is already walking through the door — plus the volume currently being turned away. Combined revenue is running at approximately $2.1 million annualized on 2026 results, with combined gross margin at 23%. A buyer bringing acquisition cost in line with market norms for a closed-door 340B operation improves that margin materially on existing volume, before any of the contracted growth is counted. It is a strategic transition designed to bring in the right partner to accelerate growth. Seller financing flexibility available. Business will be disclosed only upon execution of an NDA and buyer qualification. Offered Exclusively By: AcquiTrust Advisors- Your Advantage in Every Acquisition.

$695,000Asking Price
$2,139,272Revenue
-Cash Flow
Turn-Key NY Clinical Testing Lab | Massive Growth Upside photo
Medical Practices
+2

Turn-Key NY Clinical Testing Lab | Massive Growth Upside

NY, US

AcquiTrust Exclusive! Skip the 2-year regulatory nightmare and massive build-out costs. This is a rare, fully turn-key opportunity to step into an operational, fully permitted clinical testing laboratory in the NY Metro area. The hard work is already done: the permits are active, top-tier analyzer equipment is paid for and installed, and the infrastructure is ready for immediate high-volume sample processing. Perfect for a physician group bringing testing in-house, an existing lab operator looking to expand NY capacity, or a business buyer ready to scale an under-marketed asset. Key Investment Highlights: Fully Permitted & Certified: Active CLIA Certification and New York State Department of Health (NYS DOH) Clinical Lab Permit in place. Broad Testing Scope: Approved for Clinical Chemistry, Hematology, Qualitative Toxicology, Urinalysis, Bacteriology, and Virology. Turn-Key Equipment Included: Fully outfitted with high-throughput analyzers (Beckman Coulter AU480 units, specialized immunoassay setups) and custom LIMS software. Established Base Revenue: Produced over $390,000 in baseline 2025 revenue strictly on organic demand with zero active sales force. Immediate Growth & Marketing Opportunities: This lab has been operated passively, leaving massive money on the table for a hands-on operator: Launch Direct Physician Sales: The lab spent practically $0 on marketing. Hiring a single dedicated sales rep to target local urgent care clinics, primary care doctors, and OB/GYNs will immediately multiply sample volume. Corporate & Workplace Toxicology: Market the lab's existing toxicology capabilities to regional businesses, staffing firms, and municipal employers for lucrative, recurring pre-employment screening contracts. Digital & Direct-to-Consumer Marketing: Build a direct-to-consumer digital campaign for cash-pay specialty testing (wellness panels, hormone tracking, and rapid viral panels). Detailed Information: Facilities: Fully equipped, compliant lab space designed for efficient workflow and expansion. Support & Training: The seller will provide 30 days of full hands-on transition support to ensure a smooth transfer of operational protocols, compliance standards, and vendor relationships. Reason for Selling: Owner is divesting to focus on other core business interests. An active NYS DOH permit combined with a turnkey physical setup is almost impossible to find on the open market. Confidential listing. Business name, location, and financials released only after NDA execution. 📩 Serious inquiries only. Contact AcquiTrust for your NDA . — AcquiTrust | Owner-Led. AI-Powered. Acquisition Specialists.

$350,000Asking Price
$400,000Revenue
-Cash Flow
Turnkey Texas Retail & Wholesale Pharmacy – Fully Licensed, Contracted photo
Medical Practices
Pharmacies

Turnkey Texas Retail & Wholesale Pharmacy – Fully Licensed, Contracted

Grayson County, TX, US

An Acquitrust Exclusive. Step into a fully rehabilitated, highly optimized business foundation where all the heavy lifting has already been done. This is a rare, exclusive opportunity to acquire an established pharmacy platform that is fully licensed, contracted, and primed for massive scaling. Completely overhauled and modernized by the current ownership group, this operation offers a buyer the ultimate "plug-and-play" infrastructure with highly favorable overhead and instant revenue potential. Priced for an immediate sale, this opportunity will not last long. Key Highlights: Location: The pharmacy is located in Texas. All Major PBMs Secured: Fully active and re-established contracts with all major PBMs and insurance providers. Dual Licensing Included: Comes with both active retail pharmacy and wholesale licensing, offering multiple lucrative revenue streams. Unbeatable Low Overhead: Highly favorable lease terms with a remarkably low rent of just $1,850 per month, maximizing your profit margins from day one. Built-In Immediate Revenue: The current ownership is open to maintaining a business relationship post-closing and is willing to act as your initial wholesale customer, providing immediate cash flow and continuity! Premium Infrastructure: Existing systems, operational history, and active relationships with some of the industry’s largest primary vendors are already in place. Powerful Purchasing History: Historically, substantial inventory purchasing flowed through this operation, giving a new owner highly beneficial, established buying power. Untapped Compounding Upside: Features a dedicated, built-out non-sterile compounding room—a massive opportunity to instantly expand into high-margin customized compounding services. Why This Opportunity is Unique You are not starting from scratch. The current owners took on the painstaking work of restoring compliance, rebuilding top-tier vendor relationships, and streamlining the retail footprint. You are stepping into a clean, flawlessly structured entity with a lean operational model that is practically begging to be scaled. Whether your business model focuses on expanding retail volume, leveraging the compounding room, or heavily scaling the wholesale division, this platform offers the ultimate flexibility to grow in any direction. This is a highly confidential, exclusive sale. The foundation is built, the contracts are signed, and the business is ready for its next visionary owner. At Acquitrust Advisors, we are not just traditional business brokers. We are experienced business owners and strategic advisors who understand the true value of a well-built enterprise. We meticulously curate premium, confidential acquisition opportunities, ensuring perfect alignment and success for both buyers and sellers. NDA and proof of funds required.

$300,000Asking Price
$1Revenue
$1Cash Flow
Turnkey NJ Medical Lab w/ Huge Potential photo
Medical Devices & Products
+1

Turnkey NJ Medical Lab w/ Huge Potential

NJ, US

This is the opportunity you’ve been waiting for. Acquire a fully operational, turnkey medical diagnostics business in a prime New Jersey location. This is one of the most stable and in-demand industries in the world, and this business is already established and running. The current owner has multiple, successful businesses and simply does not have the time to give this high-potential venture the attention it deserves. Their "problem" is your "golden opportunity." This is not a distressed asset. It is a fully-equipped operation with a lot of potential, just waiting for a new owner to step in and take it to the next level. This premier clinical laboratory provides a comprehensive range of critical, high-demand testing, including: Clinical Toxicology (Drug Testing & Monitoring) Advanced Genetics & Molecular Diagnostics Routine Blood Testing & Clinical Pathology COVID-19 Testing This is the perfect acquisition for a strategic buyer, a private equity group, or an individual (MD, Ph.D., or operator) looking to enter the lucrative diagnostics market with a turnkey operation. The Opportunity: Business: Established NJ Medical Diagnostics Lab Industry: Healthcare / Clinical Diagnostics (Extremely High-Demand) Status: Turnkey & Operational Potential: This business has a lot of potential for a focused owner. Reason for Sale: Owner is spread too thin with other successful businesses. Assets: Includes all equipment, certifications, and client relationships. The owner is motivated for a quick, clean sale to the right buyer who can take over this operation.

$2,800,000Asking Price
-Revenue
-Cash Flow

What to know about pharmacy acquisitions

GW

By George Wellmer

Cofounder & CEO

Key diligence, valuation, financing, and transition considerations for buyers evaluating pharmacy acquisitions.

Sale prices have risen as larger pharmacies enter the market

Median pharmacy sale prices increased from $262,500 in 2021 to $600,000 in 2025, while median revenue grew from $675,000 to $2.5 million over the same period. This suggests that higher sale prices are being driven primarily by larger pharmacies entering the market rather than by buyers paying higher valuation multiples for similar businesses. For individual buyers, this distinction matters. The median transaction may not be representative of a small independent pharmacy in a residential neighborhood. More meaningful comparisons come from pharmacies with similar revenue, prescription volume, payer mix, and operating characteristics.

SDE margin has compressed dramatically

Discretionary earnings as a percentage of revenue dropped to 7.3% in 2025, down from 18.4% in 2024. The compression reflects structural PBM reimbursement pressure that has reduced the spread on dispensed prescriptions, plus rising operating costs that haven't been offset by reimbursement increases. Buyers should not assume historical margins continue forward. A pharmacy that ran 15% SDE margins in 2022 may run 7-8% today on the same revenue. Underwrite to current reimbursement environment, not historical performance.

Multiple valuation approaches give different answers

Common rules of thumb: 18-22% of gross sales; $200-$400 per active prescription. A pharmacy doing $2M in revenue with $200K in SDE might value between $400K (revenue multiple) and $700K (SDE multiple). The right number depends on the pharmacy's quality factors: payer mix (more cash and commercial, less Medicare/Medicaid is better), niche services (compounding, long-term care, 340B), script-file age (fresh prescriptions and active patients vs old, dormant records), and growth trajectory. Buyers should triangulate across methods.

Niche pharmacies command meaningful premiums

Compounding pharmacies, long-term care pharmacies, 340B-eligible pharmacies, and pharmacies with strong clinical service programs (vaccinations, MTM, diabetes management) trade at premiums over generic retail pharmacies. Niche pharmacies generate higher gross margins (compounding can run 40-60%+ vs 18-22% for typical retail) and have less PBM exposure on specialty work. A buyer evaluating a pharmacy should identify any niche capabilities, understand the revenue and margin contribution, and value those separately from the underlying retail dispensing business.

Inventory is meaningful and needs separate valuation

A typical pharmacy carries $150,000-$500,000 in inventory at any time. Pharmacy inventory turns 8-12 times per year. Inventory is usually a separate negotiation from the business value, paid at landed cost or at agreed adjustments. Controlled substances inventory requires specific transfer protocols (DEA Form 222 and similar). Expiring inventory is the buyer's risk if not separately negotiated. Business buyers should do an inventory walk-through with the seller and document what's near expiration and what's slow-moving.

Real estate and lease economics shape downstream options

Many pharmacies operate from leased space; some include owned real estate. Lease economics matter enormously as pharmacies are foot-traffic businesses, and a pharmacy with a strong lease in a high-visibility location is worth more than the same business in a side-street location with a short remaining lease. Where the seller owns the real estate, buyers should evaluate whether to acquire the real estate (locking in occupancy cost) or lease it back (preserving capital for working capital and acquisition financing). The two paths have meaningfully different total economics.

Frequently Asked Questions

Answers to common buyer questions for this market.

Median pharmacy sale prices reached $600,000 in 2025. Multiples typically run 2.5x-3.5x seller's discretionary earnings or 18-22% of annual gross sales. A pharmacy with $2M revenue and $200K SDE typically lists between $500K and $800K, with niche pharmacies (compounding, LTC, 340B) commanding meaningful premiums.